BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Heather L. Stevenson, Netanya S. Utay. Hepatic steatosis in HCV-infected persons in the direct-acting antiviral eraTropical Diseases, Travel Medicine and Vaccines 2016; 2(1) doi: 10.1186/s40794-016-0038-5
2
Hafsa Aziz, Muneeba Aziz, Muzaffar Lateef Gill. Analysis of Host and Viral-Related Factors Associated to Direct Acting Antiviral Response in Hepatitis C Virus PatientsViral Immunology 2018; 31(3): 256 doi: 10.1089/vim.2017.0124
3
Xiao-Wei Xu, Xiao-Xin Wu, Ke-Da Chen, Da-Zhi Chen, Hui-Lin Ou, Jun-Wei Su, Hai-Ying Yu, Hang-Ping Yao, Lan-Juan Li. Patients with chronic hepatitis C receiving sofosbuvir and ribavirin-based treatment, with or without interferon in Zhejiang, ChinaMedicine 2018; 97(38): e12403 doi: 10.1097/MD.0000000000012403
4
V. Cento, S. Barbaliscia, I. Lenci, T. Ruggiero, C.F. Magni, S. Paolucci, S. Babudieri, M. Siciliano, C. Pasquazzi, A. Ciancio, C.F. Perno, F. Ceccherini-Silberstein, V. Micheli, Y. Troshina, E. Biliotti, M. Milana, M. Melis, E. Teti, L. Lambiase, B. Menzaghi, L.A. Nicolini, S. Marenco, V.C. Di Maio, M. Aragri, A. Pecchioli, A. Bertoli, C. Sarrecchia, M. Macera, N. Coppola, M. Puoti, D. Romagnoli, A. Pellicelli, S. Bonora, S. Novati, F. Baldanti, V. Ghisetti, M. Andreoni, G. Taliani, G. Rizzardini, M. Angelico. Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real lifeClinical Microbiology and Infection 2017; 23(10): 777.e1 doi: 10.1016/j.cmi.2017.04.005